Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 4, 2011, Pages 264-268

  Pereira, Alberto M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

dopamine agonist; hyperprolactinemia; recurrence; update; withdrawal

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; QUINAGOLIDE;

CANADA; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; EUROPE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; IDIOPATHIC DISEASE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PROLACTINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

DOPAMINE AGONISTS; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PROLACTINOMA; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 79960778234     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328347c94a     Document Type: Review

References (33)

1. Liuzzi A, Dallabonzana D, Oppizzi G, et al. Lowdoses ofdopamine agonists in the long-termtreatmentofmacroprolactinomas. N Engl JMed 1985;313:656-659.
2. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60:698-705. (Pubitemid 15147556)
3. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82:876-883. (Pubitemid 27106605)
4. Sobrinho LG, Nunes MC, Calhaz-Jorge C, et al. Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours Acta Endocrinol. (Copenh) 1981; 96:24-29. (Pubitemid 11133834)
5. Verhelst J, Ab R, Maiter D, et al. Cabergoline in the treatment of hyperpro-lactinaemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84:2518-2522.
6. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. Cabergo-line Comparative Study Group. N Engl J Med 1994; 331:904-909. (Pubitemid 24299871)
7. Faglia G. Should dopamine agonist treatment for prolactinomas be lifelong? Clin Endocrinol 1991; 34:173-174.
8. Vitale G, Di Sarno A, Rota F, et al.When canwestopcabergolinetreatment in prolactinomas? Curr Opin Endocrinol Diab 2003; 10:259-264.
9. Mehmet S, Powrie JK. A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clin Endocrinol (Oxf) 2003; 58:111-113. (Pubitemid 36098857)
10. Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergo-line therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349:2023-2033. (Pubitemid 37448925)
11. Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperpro-lactinaemiaafterlong-term withdrawal of cabergolinetherapy. Clin Endocrinol (Oxf) 2007; 67:426-433. (Pubitemid 47283843)
12. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265-273. (Pubitemid 44079693)
13. Thorner MO, Mc Neilly AS, Hagan C, Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J 1974; 25:419-22.
14. Bergh T, Nillius SJ, Wide L. Menstrualfunction and serum prolactin levelsafter long-term bromocriptine teatment of hyperprolactinaemic amenorrhoea. Clin Endocrinol 1982; 16:587-593. (Pubitemid 12111429)
15. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69:500-509. (Pubitemid 19221218)
16. Brue T, Pellegrini I, Priou A, et al. Prolactinomas and resistance to dopamine agonists. Horm Res 1992; 38:84-89. (Pubitemid 23163259)
17. Rasmussen C, Bergh T, Wide L, Brownell J. CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxf) 1987; 26:321-326. (Pubitemid 17018996)
18. Rasmussen C, Brownell J, Bergh T. Clinical response and prolactin concen-tration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol (Copenh) 1991; 125:170-176.
19. Morange I, Barlier A, Pellegrini I, et al. Prolactinomas resistant to bromocrip-tine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996; 135:413-420. (Pubitemid 26364941)
20. Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63:941-945. (Pubitemid 16004299)
21. Ferrari C, Paracchi C, Mattei AM, et al.Cabergoline in the long-termtherapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 1992; 126:489-494.
22. De Luis DA, Becerra A, Lahera M, et al. Randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactine-mic patients. J Endocrinol Invest 2000; 23:428-434.
23. Winkelmann W, Allolio B, Deuss U, et al. Persisting normoprolactinemia after withdrawal ofbromocriptine long-termtherapy in patientswith prolactinomas. In: Macleod RM, Thorner MO, Scapagnini U, editors. Basic and Clinical correlates. Liviana Press: Padova, Italy; 1985. pp. 817-822.
24. Zarate A, Canales ES, Cano C, Pilonieta CJ. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 1983; 104:139-142. (Pubitemid 13000587)
25. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87:3578-3582. (Pubitemid 34879499)
26. Karunakaran S, Page RC, Wass JA. The effect of the menopauseon prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 2001; 54:295-300. (Pubitemid 32234192)
27. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of Hyperprolacti-nemia following Withdrawal of Long-Term Cabergoline Therapy. J Clin En-docrinol Metab 2009; 94:2428-2436.
28. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96:273-288.
29. Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:43-51.
30. Ho KY, Smythe GA, Compton PJ, Lazarus L. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia.Aust N ZJ Med 1985; 15:213-219. (Pubitemid 15069982)
31. Colao A, Lombardi G, Annunziato L Cabergoline Expert Opin Pharmacother 2000; 1:555-574.
32. Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiacvalve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 2008; 159:363-367.
33. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93:3348-3356.